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Influenza vaccination may limit the impact of influenza 
in the community. The aim of this study was to assess 
the effectiveness of influenza vaccination in preventing 
hospitalisation in individuals aged ≥ 65 years in Spain. 
A multicentre case–control study was conducted in 
20 Spanish hospitals during 2013/14 and 2014/15. 
Patients aged ≥ 65 years who were hospitalised with 
laboratory-confirmed influenza were matched with 
controls according to sex, age and date of hospitali-
sation. Adjusted vaccine effectiveness (VE) was calcu-
lated by multivariate conditional logistic regression. 
A total of 728 cases and 1,826 matched controls were 
included in the study. Overall VE was 36% (95% confi-
dence interval (CI): 22–47). VE was 51% (95% CI: 15–71) 
in patients without high-risk medical conditions and 
30% (95% CI: 14–44) in patients with them. VE was 
39% (95% CI: 20–53) in patients aged 65–79 years and 
34% (95% CI: 11–51) in patients aged ≥ 80 years, and 
was greater against the influenza A(H1N1)pdm09 sub-
type than the A(H3N2) subtype. Influenza vaccination 
was effective in preventing hospitalisations of elderly 
individuals.
Introduction
Influenza is an acute illness caused by influenza 
viruses. During seasonal epidemics, large numbers of 
influenza infections occur in all age groups. In most 
individuals, influenza is a self-limiting illness, but seri-
ous secondary complications appear in some of those 
infected with the influenza viruses. Influenza virus 
infection-related morbidity and mortality is a serious 
human health concern worldwide, affecting health of 
populations and economies worldwide. The illness 
may result in hospitalisation, overwhelming hospitals 
and causing excess influenza health-related deaths [1]. 
Worldwide, annual epidemics are estimated to result in 
ca 3 to 5 million cases of severe illness and ca 250,000 
to 500,000 deaths [2]. Individuals who are elderly, 
especially those with comorbidities, are particularly 
at risk for influenza-related complications and fre-
quently require hospitalisation. In an American study 
carried out in the 2005/06 through 2013/14 seasons, 
89% of all influenza-associated deaths were in people 
aged ≥ 65 years [3]. A recent French study estimated 
that 11% of all-cause deaths in elderly individuals dur-
ing the influenza season were attributable to influenza 
[4]. However, mortality is just the tip of the iceberg in 
terms of disease and the economic burden, and hospi-
talisation is also an important outcome that should be 
considered [5].
The capacity of influenza viruses to undergo grad-
ual antigenic change in their surface antigens is a 
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challenge for vaccination against seasonal influenza. 
Annual administration of the seasonal influenza vac-
cine, especially in those known to be at high risk of 
serious complications as a result of influenza, is the 
focus of current efforts to reduce the disease impact 
[1]. In the 2013/14 season, the trivalent inactivated 
vaccine administered in Spain and in all the northern 
hemisphere, contained an A/California/7/2009(H1N1)
pdm-09-like virus, an A(H3N2) virus antigenically 
similar to the cell-propagated prototype virus A/
Victoria/361/2011 and a B/Massachusetts/2/2011-like 
virus. For the 2014/15 season, the vaccine composi-
tion only changed the A/Victoria/361/2011 component 
Table 1
Distribution of influenza cases and controls aged ≥ 65 years according to demographic variables, medical conditions and 





(n = 1,826) Crude OR     95% CI     p value
n % n %
Age group 
65–79 years 411 56.5 1,016 57.0 Ref Ref
0.50
≥ 80 years 317 43.5 810 43.0 0.89 0.64–1.24
Sex 
Female 343 47.1 884 48.4 NA NA NA
Male 385 52.9 942 51.6 NA NA NA
Marital status 
Married/cohabiting 450 61.9 1,020 56.0 Ref Ref Ref
Single 39 5.4 145 8.0 0.57 0.39–0.83 0.004
Widowed 217 29.8 615 33.8 0.76 0.61–0.95 0.02
Separated/divorced 21 2.9 42 2.3 1.17 0.68–2.00 0.57
Educational level 
Without or primary 560 77.0 1,349 74.9 Ref Ref
0.07
Secondary or higher 167 23.0 453 25.1 0.81 0.64–1.01
Barthel Indexa 
0–90a 276 37.9 796 43.6 0.79 0.64–0.96
0.02
> 90a 452 62.1 1,028 56.4 Ref Ref
Smoking status 
No smoker 383 52.6 1,057 57.9 Ref Ref
0.01
Smoker/ex-smoker 345 47.4 769 42.1 1.39 1.09–1.77
High alcohol consumptionb 
Yes 16 2.2 53 2.9 0.77 0.43–1.38
0.38
No 712 97.8 1,772 97.1 Ref Ref
Number of hospital visits during the past year 
0–2 403 56.1 916 50.6 Ref Ref
0.05
≥ 3 316 43.9 896 49.4 0.82 0.67–1.00
High-risk medical conditions 
No 104 14.3 386 21.1 Ref Ref
< 0.001
Yes 624 85.7 1,440 78.9 1.73 1.35–2.22
Current-season influenza vaccine received 
Yes 359 49.3 1,053 57.7 0.73 0.61–0.87
< 0.001
No 369 50.7 773 42.3 Ref Ref
Previous-season influenza vaccine received 
Yes 376 51.6 1,054 57.7 0.78 0.66–0.93
0.005
No 352 48.4 772 42.3 Ref Ref
Pneumococcal vaccine received 
Yes 372 51.1 836 45.8 1.20 0.99–1.46
0.06
No 356 48.9 990 54.2 Ref Ref
CI: confidence interval; NA: not applicable; OR: odds ratio; Ref: reference group for comparison.
a The Barthel Index is a measurement of limitations in activity, ranging from 0 (complete dependence) to 100 (complete independence).
b High alcohol consumption defined as > 40 g/day for men and > 24 g/day for women.
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to the A/Texas/50/2012 component, an antigenically 
similar virus.
Various factors affect influenza vaccine effective-
ness (VE). One main factor is the antigenic similarity 
or dissimilarity between circulating strains and vac-
cine strains: VE decreases with increasing antigenic 
distance between vaccine components and circulat-
ing strains [6]. There was no mismatch in 2013/14 for 
the A(H1N1)pdm09 and A(H3N2) components but in 
2014/15, some degree of mismatch for the A(H3N2) 
circulating strain was observed [7,8]. Another factor is 
the influenza illness rate, which may vary substantially 
from year to year; in years with low rates, the power of 
some studies to detect significant VE may be compro-
mised [9]. Therefore, studies including more than one 
season are recommended in order to estimate VE.
The aim of this study was to assess the effectiveness 
of influenza vaccination in preventing hospitalisation 
due to laboratory-confirmed influenza in individuals 
aged ≥ 65 years during two influenza seasons (2013/14 
and 2014/15) in Spain.
Methods
Study design
We carried out a multicentre case–control study in 
20 major hospitals from seven of 17 Spanish regions 
(Andalusia, the Basque Country, Catalonia, Castile and 
Leon, Madrid, Navarra and Valencian Community), cov-
ering 1,444,688 individuals aged ≥ 65 years and rep-
resenting 16.8% of the Spanish population in this age 
group. Cases and corresponding controls admitted to 
participating hospitals between December 2013 and 
March 2015 were recruited.
Selection of cases and controls
We selected patients aged ≥ 65 years who were hospi-
talised for at least 24 hours with laboratory-confirmed 
Table 2






(n = 1,826) Crude OR     95% CI     p value
n % n %
High-risk medical conditions 
COPD 194 26.6 218 11.9 3.03 2.37–3.88 < 0.001
Chronic respiratory failure 119 16.3 208 11.4 1.64 1.26–2.14 < 0.001
Pneumonia past 2 years 91 12.5 104 5.7 2.40 1.77–3.26 < 0.001
Other lung disease 238 32.7 380 20.8 1.88 1.54–2.30 < 0.001
Cardiovascular disease 224 30.8 651 35.7 0.84 0.68–1.03 0.09
Diabetes mellitus 235 32.3 666 36.5 0.89 0.74–1.07 0.21
Renal failure with hemodialysis 16 2.2 31 1.7 1.27 0.68–2.37 0.46
Hemaglobinopathy or anaemia 89 12.2 306 16.8 0.68 0.52–0.88 0.004
AIDS 1 0.1 2 0.1 1.30 0.12–14.51 0.83
Asymptomatic HIV infection 3 0.4 1 0.1 9.00 0.94–86.52 0.06
Neurological disease 51 7.0 136 7.4 0.93 0.64–1.33 0.93
Obesity (BMI  ≥ 30 kg/m2) 174 23.9 370 20.3 1.25 1.01–1.56 0.04
Non high-risk medical conditions 
Solid organ neoplasia 103 14.1 348 19.1 0.67 0.52–0.85 0.001
Haematologic neoplasia 39 5.4 40 2.2 2.57 1.62–4.07 < 0.001
Transplantation 22 3.0 10 0.5 5.52 2.52–12.09 < 0.001
Immunosuppressive treatment 35 4.8 67 3.7 1.35 0.87–2.08 0.18
Oral corticosteroid therapy 44 6.0 43 2.4 2.54 1.62–3.97 < 0.001
Asplenia 2 0.3 8 0.4 0.66 0.14–3.11 0.60
Renal failure without hemodialysis 135 18.5 341 18.7 1.01 0.80–1.26 0.94
Nephrotic syndrome 7 1.0 14 0.8 1.14 0.45–2.88 0.78
Autoimmune disease 47 6.5 96 5.3 1.38 0.94–2.03 0.10
Chronic liver disease 28 3.8 95 5.2 0.76 0.49–1.18 0.22
Cognitive dysfunction 76 10.4 205 11.2 0.92 0.68–1.23 0.92
Neuromuscular disease 24 3.3 53 2.9 1.16 0.70–1.93 0.55
Convulsions 8 1.1 23 1.3 0.84 0.37–1.92 0.69
BMI: body mass index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; OR: odds ratio.
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(PCR, culture or immunofluorescence) influenza virus 
infection.
For each case, up to three matched controls from 
among patients aged ≥ 65 years with unplanned hos-
pital admission due to causes other than influenza 
or acute respiratory disease were selected. Controls 
were matched with each case according to sex, age 
(± 3 years) and date of hospitalisation (± 10 days). They 
were selected from patients admitted to the internal 
medicine, general surgery, otorhinolaryngology, oph-
thalmology, dermatology or traumatology services 
wards. Patients referred from nursing homes and those 
who did not provide written informed consent were 
excluded.
Data collection
The following demographic variables and pre-existing 
medical conditions were recorded: age, sex, marital 
status, educational level, smoking and high alcohol 
consumption (> 40 g/day for men and > 24 g/day for 
women), number of hospital visits during the last year, 
the Barthel Index as a measurement of limitations in 
activity (ranging from 0 (complete dependence) to 100 
(complete independence)), chronic obstructive pul-
monary disease (COPD), chronic respiratory failure, 
history of pneumonia during the last two years, other 
lung diseases, neoplasia, transplantation, immuno-
suppressive treatment, asplenia, diabetes mellitus, 
renal failure, nephrotic syndrome, autoimmune dis-
ease, AIDS, asymptomatic HIV infection, congestive 
heart disease, disabling neurological disease, obesity 
(body mass index ≥ 30 kg/m2), chronic liver disease, 
haemoglobinopathy or anaemia, cognitive dysfunction, 
convulsions and neuromuscular disease. Information 
on influenza vaccination in the current and previous 
season, and information on pneumococcal vaccination 
was collected.
Cases were considered vaccinated with the current 
influenza vaccine or pneumococcal vaccine if they had 
received a dose of the vaccine ≥ 14 days before symp-
tom onset. Controls were considered vaccinated if they 
had received a dose of the influenza vaccine ≥ 14 days 
before the onset of symptoms of the matched case. 
Influenza vaccination in the previous season in cases 
and controls was defined as administration of the sea-
sonal influenza vaccine during the preceding influenza 
season.
Statistical analysis
A bivariate comparison for matched data of demo-
graphic variables and medical conditions between 
cases and controls was made using McNemar’s test. A 
two-tailed distribution was assumed for all p values.
A univariate conditional logistic regression model was 
used to estimate the crude VE in preventing influenza 
hospitalisation. Propensity score (PS) analysis was 
used to evaluate the adjusted VE. The PS was cre-
ated using a logistic regression model with influenza 
vaccination status as the outcome and demographic 
variables, medical conditions and functional status as 
independent variables. The PS was used as a continu-
ous covariate in a final conditional logistic regression 
model.
Table 3
Crude and adjusted influenza vaccine effectiveness against hospitalisation because of influenza in individuals aged ≥ 65 
years according to influenza season, presence or absence of high-risk medical conditions, case age and type/subtype of 
influenza virus, Spain, influenza seasons 2013/14 and 2014/15











All 359/728 49.3 1,053/1,826 57.7 27% 13–39 < 0.001 36% 22–47 < 0.001
2013/14 season 208/433 48.0 602/1,038 58.0 31% 13–45 0.002 37% 19–51 < 0.001
2014/15 season 151/295 51.2 451/788 57.2 21% −3 to 40 0.08 34% 10–52 0.01
Non high-risk 
medical conditions 42/104 40.4 159/255 62.4 54% 27–71 0.001 51% 15–71 0.01
High-risk medical 
conditions 317/624 50.8 894/1,571 56.9 21% 7–32 0.01 30% 14–44 < 0.001
65–79 years of age 183/411 44.5 561/1,040 53.9 29% 11–44 0.003 39% 20–53 < 0.001
 ≥ 80 years of age 176/317 55.5 492/786 62.6 24% 0–42 0.05 34% 12–51 0.01
Influenza A 334/687 48.6 991/1,717 57.7 30% 16–41 < 0.001 37% 23–48 < 0.001
Influenza A(H1N1)
pdm09 139/325 42.8 464/823 56.4 41% 24–55 < 0.001 49% 32–62 < 0.001
Influenza A(H3N2) 138/256 53.9 393/652 60.3 22% −5 to 42 0.10 26% −3 to 47 0.08a
Influenza B 24/39 61.5 58/103 56.3 −35% −187 to 36 0.43 18% −145 to 73 0.72b
CI: confidence interval
a Statistical power: 74%.
b Statistical power: 10%.
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Using the formula VE = (1 – OR) x 100, VE was calcu-
lated globally, by season, for the presence of high-risk 
medical conditions, for age groups, for type/subtype of 
influenza virus and for each category of vaccine expo-
sure: vaccinated only in current season, only in prior 
season, in both seasons, and unvaccinated in both 
seasons as the reference group.
The analysis was performed using the SPSS version 23 
statistical package and the R version 3.3.0 statistical 
software [10].
Ethical considerations
All data collected were treated as confidential, in strict 
observance of legislation on observational studies. 
The study was approved by the ethics committees of 
the participating hospitals. Written informed consent 
was obtained from all patients included in the study.
Results
A total of 728 cases and 1,826 controls were included 
in the study. The distribution of cases and controls 
according to demographic variables, medical condi-
tions and vaccination history is shown in Table 1. A 
total of 359 cases (49.3%) and 1,053 controls (57.7%) 
had received influenza vaccination. Of the 728 cases, 
433 were from the 2013/14 season and 295 were from 
the 2014/15 season. Of the 433 cases from the 2013/14 
season, 429 (99.1%) were infected with influenza A 
virus (59.8% were A(H1N1)pdm09, 30.5% were A(H3N2) 
and 8.8% were unsubtyped), two cases were infected 
with influenza B virus and two cases were missing 
data for type and subtype. Of the 295 cases from the 
2014/15 season, 258 (87.5%) were infected with influ-
enza A virus (22.4% were A(H1N1)pdm09, 42.0% were 
A(H3N2) and 23.1% were unsubtyped) and 37 (12.5%) 
were infected with influenza B virus.
Most cases (85.7%) and controls (78.9%) had high-risk 
medical conditions (Table 2).
The overall adjusted VE against influenza hospitalisa-
tion in individuals aged ≥ 65 years was 36% (95% CI: 
22–47), without relevant differences between sea-
sons (34%, 95% CI: 10–52 in 2013/14 and 37%, 95% 
CI: 19–51 in 2014/15) (Table 3). The adjusted VE was 
greater, but not significantly different, in patients 
without high-risk medical conditions (51%, 95% CI: 
15–71) and in patients aged 65–79 years (39%, 95% CI: 
20–53). Adjusted VE was 37% (95% CI: 23–48) for all 
influenza A viruses, 49% (95% CI: 32–62) for influenza 
A(H1N1)pdm09 and 26% (95% CI: −3 to 47) for influ-
enza A(H3N2). Protection against influenza B was lower 
(VE 18%, 95% CI: −145 to 73), but the number of cases 
was very low (statistical power: 10%).
Adjusted VE against hospitalisation was 41% (95% CI: 
16–59) among those only vaccinated in the current sea-
son and 42% (95% CI: 28–54) among those vaccinated 
in both the current and previous season. VE among 
those only vaccinated in the previous season only was 
24% (95% CI: −6 to 45) (Table 4).
Discussion
The results of this study over two seasons, one with 
predominant circulation of influenza A (H1N1)pdm09 
and one with A(H3N2) predominance, show overall VE 
against hospitalisation in individuals aged ≥ 65 years 
was 36% (95% CI: 22–47).
Some studies investigating the prevention of influ-
enza hospitalisation among individuals who are elderly 
show greater VE [11,12]. In a German study using the 
screening method, VE in preventing confirmed influ-
enza hospitalisation in individuals aged ≥ 60 years 
varied between 62% in the 2011/12 season, when the 
predominant influenza virus strain was A(H3N2), and 
83% in the 2010/11 season, when the predominant 
strain was A(H1N1)pdm09 [11]. However, these levels of 
VE might be an overestimate because information on 
comorbidities was not available to adjust them by [13]. 
A Spanish case–control study for the 2014/15 season, 
when the predominant strain was A(H3N2), using test-
negative controls in 10 hospitals not included in the 
present study found a VE of 40% (95% CI: 13–59) in 
terms of preventing hospital admissions in patients 65 
Table 4
Crude and adjusted influenza vaccine effectiveness against hospitalisation because of influenza in individuals aged ≥ 65 














n % n %
Vaccinated in current season 
only 52 7.1 160 8.8 35% 7–54 0.02 41% 16–59 0.004
Vaccinated in previous 
season only 69 9.5 161 8.8 13% −20 to 37 0.39 24% −6 to 45 0.11
a
Vaccinated in both seasons 307 42.2 893 48.9 28% 13–41 0.001 42% 28–54 < 0.001
Not vaccinated 300 41.2 612 33.5 Ref Ref Ref Ref Ref Ref
CI: confidence interval; Ref: reference group for comparison.
a Statistical power: 54%.
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years of age and older [14]. A 2014 New Zealand study, 
also using a test-negative control design, found a VE of 
21% (95% CI: −82 to 66) for influenza-related hospitali-
sation in patients aged ≥ 65 years [15].
An American test-negative study by Petrie et al. [16] 
during the 2014/15 season found a VE of 48% (95% 
CI: −33 to 80) in people aged ≥ 65 years, but the num-
ber of individuals included was lower than in the pre-
sent study. A Chinese test-negative study in people 
aged > 60 years during the two seasons included in our 
study, but with a lower number of individuals than in 
our study, found a point estimate of VE of 27% (95% 
CI: −114 to 75) during the 2013/14 season. However, no 
effectiveness was observed in the 2014/15 season [17].
The possible influence of increasing age on VE has 
been investigated. In our study, adjusted VE against 
hospitalisations was 39% (95% CI: 20–53) in patients 
aged 65–79 years and 34% (95% CI: 12–51) in patients 
aged ≥ 80 years. Decreasing effectiveness has been 
linked to advanced age in different studies [12,18,19]. 
Senescence diminishes immunity to influenza infec-
tions and the response to vaccination, possibly 
explaining the lower VE in elderly individuals than in 
the general population [20].
In terms of analysing VE in older age groups, the 
German study by Remschmidt et al. found that the VE 
point estimate against laboratory-confirmed influenza 
was greater in individuals aged 60–69 years than in 
older individuals in the 2011/12 season, but the oppo-
site was observed in the 2010/11 season [11]. More 
research is needed to assess this matter.
In our study, VE was 30% (95% CI: 14–44) in patients 
with high-risk medical conditions, which was lower 
than that found in patients without these conditions. 
Similar results were obtained by other studies [16,21]. 
In contrast, a 2014/15 Canadian test-negative case–
control study of individuals aged ≥1 year by Skowronski 
et al. [22] did not find a lower age-adjusted VE in 
patients with comorbidities (16%, 95% CI: −28 to 44) 
than in patients without comorbidities (6%, 95% CI: 
−20 to 27). Comorbidities, like age, are strongly associ-
ated with a lack of response to vaccination [23]. In fact, 
one of the major mechanisms through which vaccina-
tion is thought to reduce mortality is by blunting influ-
enza-triggered exacerbations of underlying diseases 
[9]. However, despite the limited VE, the benefits of 
vaccination may be greater in patients with comorbidi-
ties because influenza is associated with a higher risk 
of severe disease and death in these individuals [24].
Similar to the results of other studies of VE in elderly 
individuals [11,25], the present study found that VE 
for subtype A(H1N1)pdm09 was greater (49%, 95% CI: 
32–62) than that for subtype A(H3N2) (26%, 95% CI: 
−3 to 47).
Small, non-significant VE differences were found 
according to season. In the 2013/14 season, an 
antigenic mismatch was observed in the B virus compo-
nent but the A(H1N1)pdm09 and A(H3N2) strains circu-
lating were analogous to the seasonal vaccine strains 
[7]. However, in some Spanish regions, specific muta-
tions of A(H1N1) and A(H3N2) strains associated with 
low VE and outbreaks in institutions were found [26]. In 
the 2014/15 season, mismatched A(H3N2) strains circu-
lated widely around the world [27], but only accounted 
for 60% of influenza A virus isolates in Spain [8]. This 
might explain why no relevant differences were found 
in VE in these two influenza seasons.
In our study, VE in individuals vaccinated only in the 
current season was similar to that of individuals vac-
cinated in both the current and previous seasons (41%, 
95% CI: 16–59 and 42%, 95% CI: 28–54, respectively), 
which does not support interference between current 
and previous vaccination. Three 2014/15 influenza sea-
son studies carried out on populations of various ages 
[16,22,28] reported that vaccination in the previous 
and current season may diminish VE only in the current 
season, suggesting negative interference from prior 
vaccination when the antigenic distance between the 
vaccine and circulating strains is large but the antigenic 
distance between vaccine components in consecutive 
seasons is small [22]. The effects of the various combi-
nations of agent-host factors involved in this phenom-
enon remain unclear and more research is required to 
determine their influence on vaccine-induced influ-
enza virus immunity in elderly individuals. However, 
in agreement with Neuzil [29], we consider that the 
current policy of administering the influenza vaccine 
every year should be maintained in the meantime. As 
the most-vulnerable elderly individuals are those with 
the most advanced age because they have a higher risk 
of hospitalisation and death compared with healthy 
elderly individuals aged 65–75 years [20], seasonal 
influenza vaccination programs in all elderly individu-
als should be reinforced.
This study has strengths and limitations. Strengths of 
this study are the matching design, the high number of 
covariates recorded and the fact that the vaccination 
status was obtained by consulting hospital records, 
vaccination cards and primary health registers.
The limitations include the fact that controls were 
not systematically swabbed and therefore they may, 
theoretically, have been infected with influenza virus. 
However, controls were patients with unplanned admis-
sion to hospital because of causes other than influenza 
or acute respiratory disease, and it seems unlikely that 
selection bias could invalidate our results. A possi-
ble confounder is the functional status; however, we 
included the Barthel Index in the propensity score 
and therefore this limitation is reasonably controlled 
for. Likewise, it is important to consider the weeks 
with influenza activity in the analysis, but because 
cases and controls were matched by admission date, 
we believe this is unlikely to invalidate the results. 
Another possible limitation is that cases and controls 
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were recruited in 20 major hospitals, but as these hos-
pitals cover 16.8% of the Spanish population aged ≥ 65 
years we believe that the study is representative of the 
older Spanish population. Also, we have not collected 
information on patients’ influenza-like illness in previ-
ous seasons, but previous episodes of influenza does 
not usually act as a confounding factor that needs to 
be controlled for in studies evaluating influenza VE 
[30]. Finally, the low statistical power in the investiga-
tion of VE against influenza B virus because of the very 
low number of cases in the two seasons studied was 
another limitation.
In conclusion, the results of this study show that influ-
enza vaccination was effective in preventing hospi-
talisations because of influenza in individuals who are 
elderly. The point estimates of the adjusted VE were 
highest in patients without high-risk medical condi-
tions, in patients in the 65–79 years of age group and 
against the influenza A(H1N1)pdm09 subtype com-
pared with the A(H3N2) subtype, although the 95% 
confidence limits overlapped. Finally, we found that 
VE was similar between vaccination only in the current 
season and vaccination in both the current and the pre-
vious seasons.
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